A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Diagnosis of glaucoma or ocular hypertension

Exclusion Criteria:

• Active ocular disease other than glaucoma or ocular hypertension

• Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)